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Background: The association between body mass index (BMI) and long-term outcomes of patients with
ICC has not been well defined. We sought to define the presentation and oncologic outcomes of patients
with ICC undergoing curative-intent resection, according to their BMI category.
Methods: Patients who underwent resection of ICC were identified in a multi-institutional database.
Patients were categorized as normal weight (BMI 18.5e24.9 kg/m2), overweight (BMI 25.0e29.9 kg/m2)
and obese (BMI30 kg/m2) according to the World Health Organization (WHO) definition. Impact of
clinico-pathological factors on recurrence-free survival (RFS) was assessed using Cox proportional haz-
ards model among patients in the three BMI categories.
Results: Among a total of 790 patients undergoing curative-intent resection of ICC in the analytic cohort,
399 (50.5%) had normal weight, 274 (34.7%) were overweight and 117 (14.8%) were obese. Caucasian
patients were more likely to be obese (66.7%, n¼ 78) and overweight (47.1%, n¼ 129) compared with
Asian (obese: 18.8%, n¼ 22; overweight: 46%, n¼ 126) and other races (obese: 14.5%, n¼ 17; overweight:
6.9%, n¼ 19)(p < 0.001). There were no differences in the presence of cirrhosis (10.9%, vs. 12.8%, vs. 12.9%),
preoperative jaundice (8.6% vs. 9.5% vs. 12.0%), or levels of CA 19e9 (75, IQR 24.6e280 vs. 50.9, IQR 17.9
e232 vs. 43, IQR 16.9e192.7) among the BMI groups (all p > 0.05). On multivariable analysis, increased
BMI was an independent risk factor for tumor recurrence (OR 1.16, 95% CI 1.02e1.32, for every 5 unit
increase).he Urban Meyer III and Shelley Meyer Chair for Cancer Research, Professor of Surgery, Oncology, Health Services
exner Medical Center, 395 W. 12th Ave, Suite 670, USA.
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For personal use onlyConclusion: Increasing BMI was associated with incremental increases in the risk of recurrence following
curative-intent resection of ICC. Future studies should aim to achieve a better understanding of BMI-
related factors relative to prognosis of patients with ICC.
© 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Introduction
In 2014, the World Health Organization (WHO) reported that
more than 1.9 billion (39%) adults are overweight and more than
600 million (13% of the world's adult population) are obese [1]. In
the United States (U.S.), these numbers are even higher, with
approximately 69% of the adult population being overweight and
35% being obese. Estimates suggest that by 2030, obesity among U.S.
adults will increase by at least 33%, such that 42e51% of the adult
population will be obese, with the prevalence of severe obesity
being 11% [2]. In light of the increase in obesity worldwide, obesity-
associated cancer has become a major health concern and an eco-
nomic burden [3]. According to the 2016 update of the International
Agency for Research on Cancer (IARC), obesity is an established risk
factor for several types of cancers, including colorectal; esophageal
adenocarcinoma, cancer of the gastric cardia, gallbladder, pancreas,
liver, kidney, breast, multiple myeloma, among others [4e7].
Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary
liver tumor with a general poor prognosis. Most patients present
with unresectable disease at the time of diagnosis, and many pa-
tients who undergo resection with curative-intent will develop
tumor recurrence [8]. In addition, reported 5-year OS after curative-
intent hepatic resection is poor, ranging from 25 to 30% [9]. While
ICC has been historically considered a rare tumor, its incidence has
been markedly increasing in the past 2 decades [10,11]. Many risk
factors for ICC development have been identified, among which
obesity has been increasingly recognized as a factor associated with
development of ICC [12e17]. Despite increasing interest in under-
standing the association of elevated BMI and ICC, to date, no study
has investigated whether increased BMI impacts prognosis of pa-
tients undergoing resection of ICC. To this end, using an interna-
tional multi-institutional database, the current study sought to
assess the impact of BMI on tumor recurrence among patients
undergoing curative-intent resection of ICC. Determining whether
increased BMI influences oncologic outcomes of patients diagnosed
with ICC may have clinical and societal implications, as overweight
and obesity constitute both prevalent and modifiable risk factors
for cancer.Methods
Data sources and study population
A multi-institutional database representing 15 major tertiary
hepatobiliary centers in the United States, Europe, Australia and
Asia was used to identify patients who underwent resection of ICC
between 1993 and 2015. The 15 institutions included The Ohio
State University, Columbus, OH; Stanford University, Stanford, CA;
University of Virginia, Charlottesville, VA; Emory University,
Atlanta, GA; Fundeni Clinical Institute of Digestive Disease,
Bucharest, Romania; Johns Hopkins Hospital, Baltimore, MD; Curry
Cabral Hospital, Lisbon, Portugal; Ospedale San Raffaele, Milan,
Italy; Royal Prince Alfred Hospital, University of Sydney, Sydney,
Australia; Eastern Hepatobiliary Surgery Hospital, Shanghai, China;
Beaujon Hospital, Clichy, France; University of Ottawa, Ottawa,chlc.min-saude.pt) at Hospital Centr
. No other uses without permission. COntario, Canada; Erasmus University Medical Centre, Rotterdam,
Netherlands; University of Verona, Verona, Italy; and Yokohama
City University School of Medicine, Yokohama, Japan. All patients
diagnosed with ICC had histological confirmation of the disease.
The study was approved by the Institutional Review Board of each
participating institution.
Patients were categorized as normal weight, overweight and
obese according to the World Health Organization (WHO) defini-
tion (normal weight: BMI 18.5e24.9; overweight: BMI 25.0e29.9;
obese: BMI30 kg/m2). Patients with missing information on BMI,
as well as individuals with data missing on any specific factor
included in the multivariable model, were excluded from the study.Data collection and follow-up
Data on standard demographic, perioperative, clinicopatholog-
ical, and tumor-related characteristics were collected. The severity
of postoperative complications was determined according to the
Clavien-Dindo Classification [18]. Based on final pathology reports,
tumor characteristics including presence of liver cirrhosis, tumor
morphology, tumor size, tumor focality, tumor number, presence of
vascular/perineural/biliary/adjacent organ invasion, lymph node
metastasis, and histological grade were assessed. Data on tumor
stage were collected according to the American Joint Committee on
Cancer (AJCC) 8th edition staging system. Patients with gallbladder
cancer infiltrating the liver bed were not included in the study.
Following surgical resection, patients were regularly followed with
serum CEA, CA19-9, and abdominal CT or MRI. Recurrence was
defined as an image showing a suspicious lesion or the presence of
a biopsy proven tumor. Recurrence was further classified as intra-
hepatic, extrahepatic, or both intra- and extrahepatic. Recurrence
interval was calculated from the date of the first surgery to the date
of recurrence. Recurrence-free survival (RFS) was calculated from
the date of surgery.Statistical analysis
Continuous variables were reported as medians and inter-
quartile ranges (IQR) and categorical variables were reported as
total counts and frequencies. To assess the association between
patient characteristics and BMI group, chi-squared tests and Wil-
coxon rank-sum tests were utilized for continuous and categorical
variables, respectively. To assess the associations between various
clinicopathological factors with RFS, a Cox proportional hazards
model was utilized. Variables for this model were selected on the
basis of clinical significance and a backwards stepwise method. All
variables were checked within the model to ensure they did not
violate the proportional hazards assumption and all continuous
variables were checked to ensure their functional form was linear.
All analyses were conducted using SAS 9.4. Statistical significance
was set at a¼ 0.05.e of Central Lisbon from ClinicalKey.com by Elsevier on August 05, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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Tumor presentation and operative characteristics
Among a total of 790 patients undergoing curative-intent
resection of ICC in the analytic cohort, 399 (50.5%) were included
in the normal weight, 274 (34.7%) in the overweight and 117 (14.8%)
in the obese BMI categories (Table 1). Median patient age and
gender were similar among patients who were of normal weight,
overweight and obese. Patients who were Caucasian were more
likely to be obese (66.7%, n ¼ 78) and overweight (47.1%, n ¼ 129)
compared with Asians (obese: 18.8%, n ¼ 22; overweight: 46%,
n ¼ 126) and other races (obese: 14.5%, n ¼ 17; overweight: 6.9%,
n¼ 19)(p < 0.001). While obese patients were more likely to have a
higher ASA score (ASA 3e4, obese: 50.5%, n ¼ 56; overweight:
29.8%, n ¼ 77; normal weight: 17.5%, n ¼ 67, p < 0.001), there were
no differences in the presence of cirrhosis (10.9%, vs. 12.8%, vs.
12.9%), preoperative jaundice (8.6% vs. 9.5% vs. 12.0%), or levels of
CA 19e9 (75, IQR 24.6e280 vs. 50.9, IQR 17.9e232 vs. 43, IQR
16.9e192.7) among obese, overweight and patients with normal
weight (all p > 0.05). Overall, only slight differences in tumor
presentation among patients in the obese, overweight and normal
weight BMI categories were observed. Specifically, obese, over-
weight and normal weight patients were as likely to present with
mass forming (MF) morphological type (92.2%, n ¼ 94, vs. 89.1%,
n ¼ 230, vs. 84.4%, n ¼ 325), periductal infiltrative (PI) (2.9%, n ¼ 3,
vs. 3.5%, n ¼ 9 vs. 6.5%, n ¼ 25) and combined MF þ PI types (2%,
n ¼ 2 vs. 3.9%, n ¼ 10 vs. 7.3%, n ¼ 28) (p ¼ 0.06). In addition,
pathological characteristics such as tumor size, tumor focality,
satellite lesions, vascular invasion, and tumor grade, among others,
were comparable among all BMI categories (all p > 0.05). The
presence of biliary invasion, however, was less likely to be observed
among normal weight patients (72.6%, n ¼ 156) compared with
overweight (83.5%, n ¼ 137) and obese patients (89.6%, n ¼ 86)
(p < 0.001). Moreover, AJCC 8th edition T and N stages were com-
parable among obese, overweight and normal weight patients
(p > 0.05). Of note, obese patients were less likely to undergo a
wedge resection (5.1%, n¼ 6 vs. 20.8%, n¼ 57, vs. 21.7%, n¼ 86) and
more likely to undergo a minor hepatectomy (35%, n¼ 41 vs. 24.8%,
n ¼ 68, vs. 23%, n ¼ 91) compared with overweight and normal
weight patients. In addition, obese patients were slightly more
likely to undergo a major hepatectomy compared with overweight
and normal weight patients (59.8%, n ¼ 70 vs. 54.4%, n ¼ 149, vs.
55.3%, n ¼ 219)(p < 0.001). Receipt of neoadjuvant therapy did not
differ between the different BMI categories (obese: 7% vs. over-
weight: 8.9%, vs. normal weight: 6.6%, p ¼ 0.55).
Perioperative outcomes
Overall, differences in perioperative outcomes of patients in the
obese, overweight and normal weight BMI categories were minor
(Table 2). Operative times (obese: 238min, IQR 150e333; over-
weight: 180min, IQR 108e310, normal weight: 180, 108e336,
p¼ 0.06) and blood loss (obese: 400ml, IQR 200e850, overweight:
300ml, IQR 200e700, normal weight: 350, IQR 200e700, p¼ 0.20)
were comparable among the three groups. On the other hand, the
incidence of lymphadenectomy was lowest among overweight
(40.7%, n¼ 110), followed by obese (46.2%, n¼ 54) and normal
weight (52.4%, n¼ 209) patients (p¼ 0.01). Nevertheless, median
number of lymph nodes harvested were comparable among the
three groups (1e5 lymph nodes: obese,11.1%, n¼ 13 vs. overweight,
12.4%, n¼ 34, vs: n¼ 641; 6 lymph nodes: obese, 88.9%, n¼ 104
vs. overweight, 87.6%, n¼ 240 vs. normal weight, 83.2%, n¼ 332)
(p¼ 0.15). Moreover, the incidence of R0 resection was also com-
parable among the three BMI categories (obese: 88.9% vs.Downloaded for Ana Quininha (ana.quininha@chlc.min-saude.pt) at Hospital Ce
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Both the incidence of postoperative complications (34.2% vs.
36.6% vs. 38.3%, p¼ 0.70) and grade of complications were similar
among obese, overweight and normal weight patients. Similarly,
the incidence of post-hepatectomy liver failure (PHLF) (obese: 0.9%,
n¼ 1 vs. overweight: 0%, vs. normal weight: 0.5%, n¼ 2, p¼ 0.39)
and bile leak (obese: 0.9%, n¼ 1 vs. overweight: 5.8%, n¼ 16, vs.
normal weight: 5%, n¼ 20, p¼ 0.09) did not differ among patients
in the three BMI categories. Interestingly, median LOS was shorter
among obese patients (9, IQR 5e15) comparedwith overweight (13,
IQR 8e18) and normal weight patients (14, IQR 9e19) (p< 0.001).
Post-operatively, there was no difference in receipt of adjuvant
chemotherapy (obese: 28% vs. overweight: 29.2% vs. normal
weight: 24.7%) or radiotherapy (obese: 5.8% vs. overweight: 9.2% vs.
normal weight: 4.5%) among patients in the three groups (both
p> 0.05).
Factors associated with RFS
Overall, no difference in RFS was observed among obese, over-
weight and normal weight BMI categories (Fig.1). Specifically, 1-, 3-
and 5-year RFS was 77.9%, 49.5% and 33.7% among obese patients
versus 81.4%, 48.7% and 36.8% among overweight patients; and
84.3%, 57.4% and 43.7%, respectively, among normal weight patients
(p¼ 0.058).
On multivariable analysis, after controlling for competing risk
factors, when BMI was analyzed as a continuous variable rather
than categorized into categorical groups, every 5 unit increase in
BMI was associated with a 16% increase in the odds of tumor
recurrence (OR 1.16, 95% CI 1.02e1.32). In addition to BMI, patients
who had metastatic lymph nodes had an increased odds of tumor
recurrence (OR 1.34, 95% CI 1.02e1.75). Of note, Asian race was also
associated with a higher odds of recurrence following curative-
intent resection of ICC (Table 3). To account for observed differ-
ences among patients of Asian race, a sub-analysis including only
Asian patients was performed. Of note, when analyzing only Asian
patients, individuals in the overweight and obese BMI categories
demonstrated a worse RFS compared with patients in the normal
weight BMI category (p< 0.001) (Fig. 2).
Patterns of recurrence
In total, 457 (57.9%) out of 790 patients developed tumor
recurrence. Among obese patients, 60.7% (n¼ 71) developed a
recurrence versus 59.1% (n¼ 162) among overweight and 56.1%
(n¼ 224) among normal weight patients. Patterns of recurrence
following initial ICC resection did not differ among patients in the
obese, overweight and normal weight BMI categories (Fig. 3).
Specifically, intrahepatic-only recurrence was observed in 60.8%
(n¼ 278) of patients (obese: 59.2%, n¼ 42 vs. overweight: 57.4%,
n¼ 93 vs. normal weight: 63.8%, n¼ 143), while 19% (n¼ 87) of
patients (obese: 19.7%, n¼ 14 vs. overweight: 21%, n¼ 34 vs.
normal weight: 17.4%, n¼ 39) experienced an extrahepatic recur-
rence, and 92 (20.1%) patients (obese: 21.1%, n¼ 15 vs. overweight:
21.6%, n¼ 35 vs. normal weight: 18.8%, n¼ 42) had combined intra-
and extrahepatic recurrence (all p> 0.05).
Discussion
While previous research have identified several pathological
variables associated with prognosis of ICC, including CA 19-9 levels,
tumor number and size, lymph node status, margin status, and
vascular invasion, to the best of our knowledge, no previous study
has specifically investigated the role of increased BMI as a prog-
nostic factor among patients with ICC [19e26]. Among patientsntre of Central Lisbon from ClinicalKey.com by Elsevier on August 05, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
Table 1
Patient characteristics and tumor presentation of normal weight, overweight and obese patients who underwent curative-intent resection of ICC.
Variables Normal Overweight Obese P-value
Patients, n (%) 399 (50.5%) 274 (34.7%) 117 (14.8%) e
Gender, n (%) 0.08
Male 233 (58.4%) 157 (57.5%) 55 (47%)
Female 166 (41.6%) 116 (42.5%) 62 (53%)
Race <0.001
Caucasian 139 (34.8%) 129 (47.1%) 78 (66.7%)
Asian 243 (60.9%) 126 (46%) 22 (18.8%)
Other 17 (4.3%) 19 (6.9%) 17 (14.5%)
Continent <0.001
North America 78 (19.5%) 78 (28.5%) 63 (53.8%)
Europe 87 (21.8%) 63 (23%) 29 (24.8%)
Asia 234 (58.6%) 123 (44.9%) 21 (17.9%)
Australia 10 (3.6%) 4 (3.4%) 4 (3.5%)
Age, years, median (IQR) 58.9 (49.2, 67.8) 60 (51.8, 69.0) 61.5 (51.7, 68.0) 0.38
ASA score, n (%) <0.001
1-2 316 (82.5%) 181 (70.2%) 55 (49.5%)
3-4 67 (17.5%) 77 (29.8%) 56 (50.5%)
Missing 16 16 6
Cirrhosis 0.15
No 330 (87.1%) 218 (87.2%) 98 (89.1%)
Yes 49 (12.9%) 32 (12.8%) 12 (10.9%)
Missing 20 24 7
CA19-9 43 (16.9e192.7) 50.9 (17.9e232) 75 (24.6e280) 0.24
Preoperative jaundice, n (%) 0.60
No 351 (88%) 247 (90.5%) 107 (91.5%)
Yes 48 (12.0%) 26 (9.5%) 10 (8.6%)
Morphological type, n (%) 0.06
MF 325 (84.4%) 230 (89.1%) 94 (92.2%)
IG 7 (1.8%) 9 (3.5%) 3 (2.9%)
PI 25 (6.5%) 9 (3.5%) 3 (2.9%)
MF þ PI 28 (7.3%) 10 (3.9%) 2 (2%)
Missing 14 16 15
Tumor size, n (%) 0.88
5 cm 167 (41.9%) 119 (43.4%) 48 (41%)
>5 cm 232 (58.1%) 155 (56.6%) 69 (59%)
Lesion, n (%) 0.50
Unifocal 342 (85.7%) 231 (84.3%) 104 (88.9%)
Multifocal 57 (14.3%) 43 (15.7%) 13 (11.1%)
Satellite lesions, n (%) 0.41
No 326 (81.7%) 212 (77.7%) 92 (78.6%)
Yes 73 (18.3%) 61 (22.3%) 25 (21.4%)
Missing 1
Major vascular invasion, n (%) 0.65
Not present 353 (88.5%) 248 (90.5%) 105 (90.5%)
Present 46 (11.5%) 26 (9.5%) 11 (9.5%)
Missing 1
Grade, n (%) 0.37
Well - Moderate 332 (84.5%) 217 (83.8%) 90 (78.9%)
Poor - Undifferentiated 61 (15.5%) 42 (16.2%) 24 (21.1%)
Missing 6 15 3
Perineural invasion, n (%) 0.49
Not present 306 (82.9%) 217 (86.5%) 85 (85%)
Present 63 (17.1%) 34 (13.5%) 15 (15%)
Missing 30 23 17
Biliary invasion, n (%) <0.001
No 59 (27.4%) 27 (16.5%) 10 (10.4%)
Yes 156 (72.6%) 137 (83.5%) 86 (89.6%)
Missing 184 110 21
Liver capsule involvement, n (%) 0.35
No 354 (88.7%) 243 (88.7%) 109 (93.2%)
Yes 45 (11.3%) 31 (11.3%) 8 (6.8%)
AJCC 8th edition N stages, n (%) 0.14
Nx 602 (76.2%) 289 (72.4%) 218 (79.6%)
N0 60 (7.6%) 33 (8.3%) 20 (7.3%)
N1 128 (16.2%) 77 (19.3%) 36 (13.1%)
AJCC 8th edition T stages, n (%) 0.81
T1a 99 (24.8%) 75 (27.4%) 28 (23.9%)
T1b 105 (26.3%) 73 (26.6%) 33 (28.2%)
T2 139 (34.8%) 90 (32.8%) 45 (38.5%)
T3 37 (9.3%) 28 (10.2%) 8 (6.8%)
T4 19 (4.8%) 8 (2.9%) 3 (2.6%)
Type of surgery, n (%) <0.001
Wedge resection 86 (21.7%) 57 (20.8%) 6 (5.1%)
Minor hepatectomy 91 (23%) 68 (24.8%) 41 (35%)
Major hepatectomy 219 (55.3%) 149 (54.4%) 70 (59.8%)
(continued on next page)
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Table 1 (continued )
Variables Normal Overweight Obese P-value
Missing 3
Neoadjuvant chemotherapy, n (%) 0.55
No 352 (93.4%) 235 (91.1%) 106 (93%)
Yes 25 (6.6%) 23 (8.9%) 8 (7%)
Missing 22 16 3
Table 2
Bivariate analysis of outcomes of normal weight, overweight and obese patients.
Variables Normal Overweight Obese P-value
Operative time median (IQR) 180 (108e336) 180 (108e310) 238 (150e333) 0.06
Blood loss median (IQR) 350 (200, 700) 300 (200, 700) 400 (200, 850) 0.20
Blood transfusion 0.91
Yes 290 (76.5%) 193 (77.5%) 80 (75.5%)
No 89 (23.5%) 56 (22.5%) 26 (24.5%)
Missing 20 25 11
Lymphadenectomy 0.01
Yes 209 (52.4%) 111 (40.7%) 54 (46.2%)
No 190 (47.6%) 162 (59.3%) 63 (53.8%)
Missing 1 0 0
LND harvest rate
1-5 67 (16.8%) 34 (12.4%) 13 (11.1%) 0.15
6 332 (83.2%) 240 (87.6%) 104 (88.9%)
Lymph node ratio 0.21
0 88 (53.3%) 62 (63.3%) 34 (69.4%)
<0.25 19 (11.5%) 11 (11.2%) 5 (10.2%)
0.26e0.50 23 (13.9%) 6 (6.1%) 2 (4.1%)
>0.50 35 (21.2%) 19 (19.4%) 8 (16.3%)
Missing 234 176 68
R1 resection 48 (12%) 23 (8.4%) 13 (11.1%) 0.32
R0 resection 351 (88%) 251 (91.6%) 104 (88.9%)
Complication 0.70
Yes 153 (38.3%) 100 (36.6%) 40 (34.2%)
No 246 (61.7%) 173 (63.4%) 77 (65.8%)
Missing 1 0 0
Grade of complication 0.29
Clavien-Dindo I 56 (14%) 40 (14.6%) 11 (9.4%)
Clavien-Dindo II 40 (10%) 31 (11.3%) 17 (14.5%)
Clavien-Dindo III 283 (70.9%) 195 (71.2%) 79 (67.5%)
Clavien Dindo-IV 12 (3%) 6 (2.2%) 7 (6%)
Clavien-Dindo V 8 (2%) 2 (0.7%) 3 (2.6%)
Bile leak 20 (5%) 16 (5.8%) 1 (0.9%) 0.09
PHLF 2 (0.5%) 0 (0.0%) 1 (0.9%) 0.39
LOS, median (IQR) 14 (9e19) 13 (8e18) 9 (5e15) <0.001
30- day readmission 17 (4.6%) 15 (6.1%) 7 (6.7%) 0.61
90-mortality 6 (1.6%) 2 (0.8%) 4 (3.8%) 0.12
Adjuvant chemotherapy 95 (24.7%) 79 (29.2%) 30 (28%) 0.42
Adjuvant radiotherapy 17 (4.5%) 24 (9.2%) 6 (5.8%) 0.06
K. Merath et al. / European Journal of Surgical Oncology 45 (2019) 1084e10911088with ICC, the ability to predict prognosis accurately after surgical
resection remains poor, with most prognostic/predictive tools
performing only moderately at best [27,28]. Accurate estimation of
recurrence risk and long-term survival is important, however, to
guide perioperative management of patients undergoing surgical
resection with curative-intent, as well as for adequate informed
consent and shared decision-making. As such, the current study is
important because it reports one of the largest multi-institutional
experiences on the surgical management of ICC. Of note, we
found that increased BMI among patients undergoing curative-
intent resection of ICC is associated with increased risk of recur-
rence. The understanding of risk factors associated with poor
prognosis is important to guide future interventions directed at
improving long-term outcomes of patients with ICC.
Calle et al. reported on a population of more than 900,000 U.S.
adults and noted that obesity was associated with increased death
rates for all cancers combined, as well as for cancers at multiple
specific sites [29]. Indeed, a growing body of literature hasDownloaded for Ana Quininha (ana.quininha@chlc.min-saude.pt) at Hospital Ce
For personal use only. No other uses without permissiodemonstrated that obese patients with cancer often have worse
oncologic outcomes independent of disease presentation and stage.
For example, among patients with early stage breast cancer treated
with curative-intent, obesity has been associated with locoregional
recurrence and distant metastases, as well as breast-cancer specific
mortality [30,31]. In addition, a separate study that examined pa-
tients with stage IIeIII colon cancer reported that BMI> 35 kg/m2
was associated with a 38% increased risk of recurrence and a 36%
increased risk of disease-specific mortality [32]. Similarly, in a
multicenter study of patients undergoing radical cystectomy,
Chromecki et al. identified obesity as an independent predictor of
disease recurrence (HR 1.67, 95% CI 1.46e1.91) and cancer-specific
mortality (HR 1.43, 95% CI 1.24e1.66) [33]. Similar associations
between increased BMI and poor oncologic outcomes have been
observed in other gastrointestinal solid tumors, genitourinary and
hematological malignancies [29,34e37]. To date, among patients
with primary liver cancers, previous research has almost
completely focused on patients with hepatocellular carcinomantre of Central Lisbon from ClinicalKey.com by Elsevier on August 05, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
Fig. 1. Recurrence-free survival of obese, overweight and normal weight patients.
Table 3
Multivariable analysis of factors associated with recurrence-free survival.
OR CI p-value
BMI (þ5 units) 1.16 1.02e1.32 0.021
Age (þ5 years) 1.09 1.03e1.15 0.001
Metastatic lymph nodes
Yes 1.34 1.02e1.75 0.037
No ref e
Race
Asian 1.66 1.23e2.42 <0.001
Others ref e
Fig. 2. Recurrence-free survival of obese, overweight and normal weight patients in a
subset of patients of Asian race.
Fig. 3. Patterns of tumor recurrence among obese, overweight and normal weight
patients.
K. Merath et al. / European Journal of Surgical Oncology 45 (2019) 1084e1091 1089(HCC) [38e41]. For example, Shinkawa et al. reported that obesity
was an independent risk for worse RFS (HR 2.8; 95% CI 1.3e6.1)
among HCV-related HCC patients with preoperative sustained
virological response [40]. Moreover, Mathur et al. noted that obese
and overweight individuals had doubled the incidence of recur-
rence compared with non-obese group after transplantation for
HCC (15% vs. 7%, p< 0.05) [39].
After surgical resection of ICC, the incidence of recurrence canDownloaded for Ana Quininha (ana.quininha@chlc.min-saude.pt) at Hospital Centr
For personal use only. No other uses without permission. Cbe high ranging from 46% to 65% [42]. Although several pathologic
characteristics associated with less favorable ICC prognosis have
been identified, currently available nomograms and staging sys-
tems have demonstrated only a limited ability to predict RFS and
OS. In fact, our own group demonstrated that even among patients
with “favorable” tumor pathology e i.e., unifocal disease, MF-ICC
morphology, no lymph node metastasis, tumor size <5 cm, and
well-to-moderately differentiated tumor grade e most patients
have considerably shorter recurrence intervals than would be
predicted [27]. Several authors have hypothesized that the subop-
timal predictive ability of current prognostic tools developed re-
lates to the need to include other - yet-to-be identified - prognostic
variables [26,43,44]. Interestingly, while predictive tools have
considered clinical characteristics such as patient age and sex, no
previous studies have included BMI or race as possible prognostic
factors [26,27,43e45]. As such, the findings of the current study
were particularly relevant, as we demonstrated that increasing BMI
was independently associated with incremental increases in the
risk of recurrence after curative-intent resection among patients
with ICC. Specifically, onmultivariable analysis of factors associated
with recurrence, every 5 unit increase in patient BMI was associ-
ated 16% increase in the risk of recurrence. Of note, Asian race was
also an independent prognostic factor for tumor recurrence, and
among this subset of patients, patients in the overweight and
obesity BMI categories had significantly worse RFS (Fig. 2).
While the current study was not designed to elucidate the
mechanistic underpinnings of increased BMI relative to recurrence
of ICC, several findings were notable. Despite the fact that initial
tumor presentation, perioperative outcomes and patterns of
recurrence did not differ among the different BMI categories,
increasing BMI was still associated with increased odds of tumor
recurrence. These results reinforce the hypothesis that factors
beyond classical tumor characteristics impact prognosis of patients
with ICC. Recently, advances in epigenomics studies have demon-
strated important associations among different gene expression
patterns and different states of diseases and/or medical conditions
[46]. DNAmethylation, awell-known and critical regulation level of
the epigenetic machinery, is easily modulated by environmental
factors [47e49]. Several studies have demonstrated that altered
DNA methylation patterns in some metabolically important genes
are a consequence of high BMI [50e53]. In fact, Gu et al. recently
described BMI-associated epigenetic alterations in chol-
angiocarcinomas [54]. Additionally, genomic alterations were also
described among etiologically distinct subtypes ofe of Central Lisbon from ClinicalKey.com by Elsevier on August 05, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
K. Merath et al. / European Journal of Surgical Oncology 45 (2019) 1084e10911090cholangiocarcinoma [55]. Specifically, Jusakul et al. reported four
distinct subtypes of ICC with different clinical and genomic char-
acteristics that have distinct prognoses. Moreover, dysfunctional
adipose tissue in obese patients can release adipokines that elevate
levels of pro-inflammatory factors, producing a state of chronic
inflammation [56e59]. One such adipokine is CXCL5, a chemokine
involved in angiogenesis, which when overexpressed is associated
with advanced tumor stages, local invasion and increased meta-
static potential. For example, among patients with pancreatic
cancer, overexpression of CXCL5 has been associated with poor
oncologic outcomes [60]. Importantly, a recent study demonstrated
that the expression of CXCL5 was an independent predictor of OS
and time to recurrence in patients with ICC [61]. As obesity pro-
motes a state of chronic inflammation, future studies will need to
investigate the associations of distinct gene expression patterns, as
well as genetic mutations, among patients with increased BMI.
The results of the current study should be interpreted in light of
several limitations. Similar to other retrospective and multi-
institutional studies, the current analysis may have been subject
to selection bias and heterogeneity in perioperative ICC treatments.
In addition, the definition of obesity, overweight and normal
weight was based on the calculation of patient BMI, which cannot
differentiate between adipose tissue and lean mass. Therefore, BMI
may underestimate the prevalence of visceral obesity in the pop-
ulation, which might result in potential biases of the association
between obesity and outcomes towards the null effect [57].
Nevertheless, due to non-feasibility of quantification of visceral
adipose tissue through imaging for population-based studies, BMI
has been widely adopted and accepted for the definition of weight
categories for research purposes [54]. Moreover, the database did
not provide information regarding the presence of non-alcoholic
steatohepatitis (NASH) or non-alcoholic fatty liver disease
(NAFLD). While it is recognized that the incidence of NAFLD and
NASH is more prevalent among overweight and obese patients,
previous studies using a similar cohort of patients have found that
recurrence-free and overall survival after hepatic resection of ICC
are comparable in NASH versus non-NASH patients [62]. The
database also lacked data on metabolic syndrome and the comor-
bidities that define the syndrome, as well as other comorbidities
such as chronic kidney disease, chronic obstructive pulmonary
disease, among others.
In conclusion, when BMI was analyzed as continuous variable,
incremental increases in BMI were associated with increased risk of
recurrence following curative-intent resection of ICC. In addition,
among Asian patients the impact of overweight and obesity on RFS
was particularly pronounced. Given the increasing incidence of ICC,
parallel to the continuous increase in the incidence of overweight,
obese and severely obese adults worldwide, a better characteriza-
tion of the prognostic role of patients’ BMI in ICC is needed to guide
appropriate interventions. Future research aimed at understanding
factors that go beyond classic pathologic characteristics of ICC and
elucidate mechanisms associated with worse outcomes is
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